dc.contributor.author
Simancas-Racines, Daniel
dc.contributor.author
Montero-Oleas, Nadia
dc.contributor.author
Vernooij, Robin W. M.
dc.contributor.author
Arevalo-Rodriguez, Ingrid
dc.contributor.author
Fuentes, Paulina
dc.contributor.author
Gich, Ignasi
dc.contributor.author
Hidalgo, Ricardo
dc.contributor.author
Martinez-Zapata, Maria José
dc.contributor.author
Bonfill, X. (Xavier)
dc.contributor.author
Alonso-Coello, Pablo
dc.contributor.author
Universitat Autònoma de Barcelona
dc.identifier
https://ddd.uab.cat/record/211404
dc.identifier
urn:10.1111/jebm.12330
dc.identifier
urn:oai:ddd.uab.cat:211404
dc.identifier
urn:pmid:30511477
dc.identifier
urn:pmcid:PMC6587995
dc.identifier
urn:pmc-uid:6587995
dc.identifier
urn:articleid:17565391v12p113
dc.identifier
urn:scopus_id:85058035643
dc.identifier
urn:oai:egreta.uab.cat:publications/cbadde47-fba6-4ed0-b506-fd5b49882b12
dc.identifier
urn:oai:pubmedcentral.nih.gov:6587995
dc.description.abstract
Red blood cell (RBC) transfusions are essential in health care. The quality of recommendations included in clinical practice guidelines (CPG), regarding this intervention, has not been systematically evaluated. This paper systematically assessed CPGs for RBC-transfusion, to appraise their methodological quality, to explore changes in quality over time, and to assess the consistency of the hemoglobin threshold (HT) recommendations. We searched for CPGs that included recommendations of RBC-transfusion in generic databases, compiler entities, registries, clearinghouses and guideline developers. Three reviewers extracted data on CPGs characteristics and HT recommendations, independently appraised the quality of the studies using AGREE II and resolved disagreements by consensus. We examined 16 CPGs. Mean scores (mean ± SD) were: scope and purpose (59.4% ± 19.8%), stakeholder involvement (43.2% ± 22.6%), rigor of development (50% ± 25%), clarity of presentation (74.4% ± 12.6%), applicability (19.4% ± 18.8%), and editorial independence (41% ± 30%). Seven CPGs recommended a restrictive strategy for RBC transfusion; four CPGs gave a guarded statement considering an HT of 7 g/dL, as safe to prescribe an RBC transfusion. Eight CPGs did not provide an HT stating that RBC transfusions should not be prescribed by HT alone. Only 3 out of the 16 evaluated CPGs were "recommended" by the independent evaluators. Four domains "stakeholder involvement," "rigor of development," applicability," and "editorial independence" had serious shortcomings. Recommendations about the use of an HT for RBC-transfusion were heterogeneous among guidelines. Greater efforts are needed to provide high-quality CPGs in the RBC-transfusion practice.
dc.format
application/pdf
dc.relation
Journal of Evidence-Based Medicine ; Vol. 12 (december 2018), p. 113-124
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
dc.rights
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
Blood transfusion
dc.subject
Clinical practice guidelines
dc.subject
Red blood cells
dc.subject
Systematic review
dc.title
Quality of clinical practice guidelines about red blood cell transfusion